OR of hospitalization, ICU admission, mortality, susceptibility to SARS-CoV-2 and COVID-19 progression from the last 6 month exposure to dapagliflozin
| . | Cases . | Controls . | Adjusted OR CI 95% . | P value . |
|---|---|---|---|---|
| HOSPITALIZATION Risk of hospitalization due to COVID-19 versus healthy controls | 26/3060 (0.8%) | 331/56 785 (0.6%) | 0.98 (0.65–1.48) | 0.915 |
| ICU ADMISSION Risk of ICU admission due to COVID-19 versus healthy controls | 3/228 (1.3%) | 26/4398 (0.6%) | 1.21 (0.34–4.25) | 0.767 |
| IN-HOSPITAL DEATH Risk of mortality due to COVID-19 versus healthy controls | 6/413 (1.5%) | 46/7408 (0.6%) | 1.33 (0.53–3.30) | 0.543 |
| PROGRESSION Risk of hospitalization among subjects with PCR+ | 26/3060 (0.8%) | 118/26 757 (0.4%) | 0.65 (0.40–1.06) | 0.086 |
| SUSCEPTIBILITY Risk of PCR+ versus not having COVID | 144/29 817 (0.5%) | 331/56 785 (0.6%) | 1.31 (1.05–1.62) | 0.015 |
| . | Cases . | Controls . | Adjusted OR CI 95% . | P value . |
|---|---|---|---|---|
| HOSPITALIZATION Risk of hospitalization due to COVID-19 versus healthy controls | 26/3060 (0.8%) | 331/56 785 (0.6%) | 0.98 (0.65–1.48) | 0.915 |
| ICU ADMISSION Risk of ICU admission due to COVID-19 versus healthy controls | 3/228 (1.3%) | 26/4398 (0.6%) | 1.21 (0.34–4.25) | 0.767 |
| IN-HOSPITAL DEATH Risk of mortality due to COVID-19 versus healthy controls | 6/413 (1.5%) | 46/7408 (0.6%) | 1.33 (0.53–3.30) | 0.543 |
| PROGRESSION Risk of hospitalization among subjects with PCR+ | 26/3060 (0.8%) | 118/26 757 (0.4%) | 0.65 (0.40–1.06) | 0.086 |
| SUSCEPTIBILITY Risk of PCR+ versus not having COVID | 144/29 817 (0.5%) | 331/56 785 (0.6%) | 1.31 (1.05–1.62) | 0.015 |
OR adjusted for sex, age and comorbidities: hypertension, diabetes, COPD, obesity, ischaemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation, chronic renal failure, cancer, asthma, current smoker, current use of other pharmacological treatment (antihypertensives, diuretics, non-steroidal anti-inflammatory drugs, hypolipidaemic agents, anticoagulants, antiplatelet agents and glucocorticoids) and chronic proxy (number of different chronic treatments).
OR of hospitalization, ICU admission, mortality, susceptibility to SARS-CoV-2 and COVID-19 progression from the last 6 month exposure to dapagliflozin
| . | Cases . | Controls . | Adjusted OR CI 95% . | P value . |
|---|---|---|---|---|
| HOSPITALIZATION Risk of hospitalization due to COVID-19 versus healthy controls | 26/3060 (0.8%) | 331/56 785 (0.6%) | 0.98 (0.65–1.48) | 0.915 |
| ICU ADMISSION Risk of ICU admission due to COVID-19 versus healthy controls | 3/228 (1.3%) | 26/4398 (0.6%) | 1.21 (0.34–4.25) | 0.767 |
| IN-HOSPITAL DEATH Risk of mortality due to COVID-19 versus healthy controls | 6/413 (1.5%) | 46/7408 (0.6%) | 1.33 (0.53–3.30) | 0.543 |
| PROGRESSION Risk of hospitalization among subjects with PCR+ | 26/3060 (0.8%) | 118/26 757 (0.4%) | 0.65 (0.40–1.06) | 0.086 |
| SUSCEPTIBILITY Risk of PCR+ versus not having COVID | 144/29 817 (0.5%) | 331/56 785 (0.6%) | 1.31 (1.05–1.62) | 0.015 |
| . | Cases . | Controls . | Adjusted OR CI 95% . | P value . |
|---|---|---|---|---|
| HOSPITALIZATION Risk of hospitalization due to COVID-19 versus healthy controls | 26/3060 (0.8%) | 331/56 785 (0.6%) | 0.98 (0.65–1.48) | 0.915 |
| ICU ADMISSION Risk of ICU admission due to COVID-19 versus healthy controls | 3/228 (1.3%) | 26/4398 (0.6%) | 1.21 (0.34–4.25) | 0.767 |
| IN-HOSPITAL DEATH Risk of mortality due to COVID-19 versus healthy controls | 6/413 (1.5%) | 46/7408 (0.6%) | 1.33 (0.53–3.30) | 0.543 |
| PROGRESSION Risk of hospitalization among subjects with PCR+ | 26/3060 (0.8%) | 118/26 757 (0.4%) | 0.65 (0.40–1.06) | 0.086 |
| SUSCEPTIBILITY Risk of PCR+ versus not having COVID | 144/29 817 (0.5%) | 331/56 785 (0.6%) | 1.31 (1.05–1.62) | 0.015 |
OR adjusted for sex, age and comorbidities: hypertension, diabetes, COPD, obesity, ischaemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation, chronic renal failure, cancer, asthma, current smoker, current use of other pharmacological treatment (antihypertensives, diuretics, non-steroidal anti-inflammatory drugs, hypolipidaemic agents, anticoagulants, antiplatelet agents and glucocorticoids) and chronic proxy (number of different chronic treatments).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
